Prognostic impact of neoadjuvant aglepristone treatment in clinicopathological parameters of progesterone receptor‐positive canine mammary carcinomas |
| |
| Authors: | S Guil‐Luna Y Millán J De Andres E Rollón V Domingo J García‐Macías R Sánchez‐Céspedes J Martín de las Mulas |
| |
| Institution: | 1. Department of Comparative Pathology, Veterinary Medicine Faculty, University of Córdoba, Córdoba, Spain;2. Small Animal Clinic Thor, Córdoba, Spain;3. Small Animal Clinic Canymar, Cádiz, Spain;4. Small Animal Clinic Recuerda, Granada, Spain |
| |
| Abstract: | Neoadjuvant treatment of canine mammary carcinomas with the progesterone receptor (PR) antagonist aglepristone has a PR expression‐related inhibiting effect on proliferation index (PI). The aim of this study was to evaluate the effect of the treatment in the disease‐free period (DFP) and overall survival (OS) of canine mammary carcinomas. Fifty female dogs with mammary carcinomas were treated with aglepristone (n = 34) or oil vehicle (n = 16) before surgery (day 15). PR expression and PI were analysed by immunohistochemistry in samples taken at days 1 and 15. Epidemiological and clinicopathological data were assessed. DFP and OS data were retrieved every 4–6 months for at least 24 months after surgery. Aglepristone treatment increased DFP of animals bearing PR+ tumours with size smaller than 3 cm, complex and mixed tumours, with histologic grades I and II, and with PI ≤ 10%. Although further studies are necessary, current evidence points to treatment with aglepristone as useful for the management of canine mammary tumours. |
| |
| Keywords: | comparative oncology oncology pathology small animal tumour biology |
|
|
